Pacira BioSciences Faces Contested Director Election and Seeks Approval for Significant Equity Plan Expansion Amidst Activist Pressure
Summary
Pacira BioSciences is engaged in a proxy contest with activist investor DOMA Perpetual over board seats and is seeking approval for a substantial increase in its equity compensation plans, which could lead to significant dilution.
Key Events
-
Contested Director Election
Activist investor DOMA Perpetual Capital Management LLC has nominated three directors in opposition to the board's recommended slate for the upcoming annual meeting, leading to a proxy contest.
-
Significant Equity Plan Expansion Proposed
The company is seeking shareholder approval to add 2.2 million new shares to its 2011 Stock Incentive Plan and 800,000 shares to its 2014 Employee Stock Purchase Plan, totaling 3 million new shares. This represents approximately 7.6% potential dilution based on current outstanding shares, with a total equity overhang of 33.5% of outstanding shares.
-
Response to Low Say-on-Pay Vote
Following a 39.5% advisory vote on executive compensation in 2025, the company has introduced Performance Share Units (PSUs) for executives in 2026 and refined its compensation peer group to address shareholder feedback.
-
Board Defends Strategy and Nominees
The board is actively defending its strategic direction and its highly qualified director nominees, emphasizing recent board refreshment and positive operational performance in 2025, including record revenues and net income, and a favorable patent litigation settlement.
Analysis
Pacira BioSciences is facing a contested director election at its upcoming annual meeting, with activist investor DOMA Perpetual Capital Management LLC nominating three directors in opposition to the board's slate. This proxy statement details the board's strong recommendation against the activist nominees and its defense of the company's strategic direction and recent performance. Concurrently, the company is seeking shareholder approval for a significant expansion of its equity incentive plans, requesting 2.2 million new shares for its 2011 Stock Incentive Plan and 800,000 shares for its Employee Stock Purchase Plan. This represents a substantial potential dilution of approximately 7.6% based on current outstanding shares, with the total overhang (outstanding awards plus future grants) potentially reaching 33.5% of outstanding shares. This comes after a very low 39.5% Say-on-Pay approval in 2025, to which the company has responded by introducing Performance Share Units (PSUs) for executives and refining its compensation peer group for 2026. The ongoing proxy contest and the significant potential dilution from the equity requests create considerable uncertainty and pressure on management and the board.
At the time of this filing, PCRX was trading at $24.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $18.80 to $27.64. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.